Article may be outdated

This article is 2 days old. Some details may have changed since publication.

Quartz·1 min read·medium

Merck won FDA approval for the first cholesterol pill to rival powerful injectables

Cris Tolomia
AI Summary

Merck has received FDA approval for Lipfendra, a once-daily pill that significantly reduces LDL cholesterol. This new medication serves as a competitive alternative to existing injectable cholesterol treatments.

Lipfendra, a once-daily pill, reduced LDL cholesterol by up to 59% in late-stage trials, rivaling existing injectable treatments

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthbusiness

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in